Trial Profile
A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 15 Nov 2021 Results assessing the hepatocellular carcinoma risk in chronic hepatitis B patients enrolled in prospective, randomized, tenofovir (TFV)-based trials, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 28 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00507507).